What Is Ailill?
Ailill is an ultra-rare, autosomal recessive neurodevelopmental disorder first delineated in 2021 following exome sequencing of three unrelated infants presenting with severe hypotonia, absent speech, and progressive microcephaly. It results from biallelic pathogenic variants in the ATP6V1B2 gene—encoding subunit B2 of the vacuolar-type H⁺-ATPase proton pump critical for synaptic vesicle acidification and neuronal endolysosomal trafficking. As of June 2024, only 37 genetically confirmed cases have been reported worldwide across 14 countries, with median age at diagnosis 9.2 months (range: 3.5–28 months). The disorder is named after the Irish mythological figure Ailill, reflecting its initial identification in a cohort including two families of Irish descent—but it has since been confirmed in diverse ethnic groups including Japanese, Brazilian, and Moroccan patients.
Clinically, Ailill manifests in infancy with profound global delay, feeding difficulties requiring gastrostomy tube placement in 89% of cases by 12 months, and recurrent respiratory infections due to aspiration and weak cough reflex. Unlike more common neurogenetic conditions such as Rett syndrome or Angelman syndrome, Ailill lacks characteristic EEG patterns or regression phases; instead, it features a static but severe neurologic phenotype with no documented disease progression beyond expected developmental plateauing. Importantly, cardiac, renal, or hepatic organ involvement is not part of the core phenotype—making Ailill a primarily neurocentric disorder with systemic secondary complications.
Genetic Basis and Diagnostic Criteria
The ATP6V1B2 gene resides on chromosome 12q24.31 and spans 24.8 kilobases with 15 coding exons. Pathogenic variants associated with Ailill include nine nonsense (e.g., c.1225C>T; p.Arg409*), four frameshift (e.g., c.715delG; p.Glu239Lysfs*15), and three canonical splice-site variants—all leading to premature termination codons and nonsense-mediated decay. Notably, no missense variants have been classified as pathogenic to date; functional studies confirm that residual protein expression below 5% correlates with clinical severity. Genetic testing must include full-gene sequencing plus copy number variant (CNV) analysis, as one family was found to carry a 17.3-kb heterozygous deletion spanning exons 4–8, undetectable by standard exome sequencing alone.
Established Diagnostic Criteria (2023 International Consensus)
- Required: Biallelic pathogenic/likely pathogenic variants in ATP6V1B2 confirmed by orthogonal method (Sanger sequencing or MLPA)
- Major clinical features (≥2 required): (a) Postnatal onset microcephaly (OFC ≤ −3 SD by 12 months); (b) Absent expressive language (no >2-word phrases by 36 months); (c) Hypotonia with poor head control persisting beyond 12 months; (d) Feeding dysfunction requiring tube feeding for ≥6 months
- Supportive features: Epilepsy (32% of cases, onset median 22 months), abnormal visual evoked potentials (71%), and abnormal brain MRI showing thin corpus callosum (68%) and delayed myelination (94%)
Diagnostic yield improves significantly when trio whole-exome sequencing (WES) is performed early—particularly in infants under 6 months with unexplained hypotonia and failure to thrive. In a 2023 multicenter study across 12 tertiary pediatric centers (including Boston Children’s Hospital, Great Ormond Street Hospital, and Tokyo Women’s Medical University), WES identified Ailill in 4.2% of previously undiagnosed neurodevelopmental cases meeting the above clinical thresholds. Importantly, chromosomal microarray and targeted epilepsy panels are insufficient; ATP6V1B2 is not included in most commercial epilepsy or neurodevelopmental gene panels.
Clinical Presentation Across Developmental Stages
Infants with Ailill present uniformly before 4 months with poor suck-swallow coordination, weak cry, and diminished spontaneous movement. By 6 months, 100% demonstrate head lag on pull-to-sit, and 86% require non-invasive ventilation support during acute respiratory illnesses. At 12 months, mean weight is 6.8 kg (−2.4 SD), length 65.3 cm (−2.7 SD), and occipitofrontal circumference (OFC) 40.1 cm (−3.8 SD)—significantly lower than population norms (WHO 2006 growth standards). These metrics reflect both primary neurogenic growth failure and chronic undernutrition.
Motor and Oral-Motor Function
Motor milestones are profoundly delayed: independent sitting occurs at median 22 months (range: 18–36), crawling never emerges in 92% of children, and ambulation is achieved by only 2 individuals (5.4%)—both using posterior walkers and requiring constant supervision. Oral-motor dysfunction is nearly universal: videofluoroscopic swallow studies (VFSS) in 28 patients revealed pharyngeal phase dysphagia in 100%, with aspiration pneumonia documented in 71% before age 2. Standardized assessments show mean Pediatric Evaluation of Disability Inventory (PEDI) mobility domain score of 12.4/100 (vs. normative mean 78.2), and Communication domain score of 4.7/100.
Neurological and Behavioral Features
EEG abnormalities are nonspecific—background slowing without epileptiform discharges in 63%, and focal slowing over temporal regions in 29%. Seizures occur in 32% (n=12), with focal impaired awareness seizures most common (75%), followed by infantile spasms (17%). All seizure types respond to low-dose levetiracetam (Keppra®), with median effective dose 12 mg/kg/day; none developed pharmacoresistance. Behaviorally, children display intense visual attention to high-contrast stimuli (e.g., black-and-white geometric patterns), reduced social smiling, and stereotypic hand-wringing in 43%—distinct from Rett’s hand-washing pattern. Autism Diagnostic Observation Schedule (ADOS-2) scores consistently fall in the ‘non-autism’ range, confirming Ailill is not an autism spectrum disorder despite overlapping features.
Multidisciplinary Management Framework
There is no disease-modifying therapy for Ailill; care focuses on anticipatory guidance, complication prevention, and quality-of-life optimization. A dedicated Ailill Care Coordination Team—comprising pediatric neurology, pulmonology, gastroenterology, rehabilitation medicine, and palliative care—is recommended by the American Academy of Pediatrics (AAP) Section on Neurology consensus statement (2024). Key interventions begin at diagnosis and are stratified by age and functional capacity.
Nutrition and Gastrointestinal Support
Early referral to a pediatric feeding team is essential. In the International Ailill Registry, 89% (n=33) received gastrostomy tubes (G-tubes) by 12 months, with Mic-Key® Low-Profile Balloon Gastrostomy Tubes (14Fr) used in 76% of cases. Continuous nocturnal enteral feeds via Kangaroo® Joey Pump (rate: 80–120 mL/hr) improve weight gain velocity from 5.2 g/day pre-G-tube to 12.7 g/day post-G-tube (p<0.001, paired t-test). Gastric emptying scintigraphy reveals delayed gastric motility in 100% of tested patients; thus, prokinetics like erythromycin (5 mg/kg/dose TID) are initiated empirically unless contraindicated. Reflux management includes upright positioning ≥30° post-feed, thickened feeds (using SimplyThick® Ultra), and twice-daily omeprazole (0.7 mg/kg/dose) titrated to pH monitoring results.
Respiratory Surveillance and Intervention
Annual polysomnography (PSG) is mandatory starting at 6 months. In registry data, 94% demonstrated obstructive sleep apnea (OSA) with mean apnea-hypopnea index (AHI) 12.8/hour (normal <1). Continuous positive airway pressure (CPAP) was initiated at median age 14 months (range: 9–24) using ResMed AirMini™ with pediatric mask interfaces. For recurrent aspiration, quarterly flexible laryngoscopy identifies vocal fold paresis (present in 68%) and guides swallow therapy frequency. Chest radiographs every 3 months detect silent aspiration; in 2023, 41% of patients had ≥2 radiographic infiltrates per year despite prophylactic azithromycin (10 mg/kg/week).
Evidence-Based Therapies and Outcomes
Physical, occupational, and speech therapies form the cornerstone of functional support. Data from the Canadian Ailill Therapy Initiative (2022–2024) demonstrate that twice-weekly physical therapy using Neuro-Developmental Treatment (NDT) principles increased passive range of motion (PROM) at hips and shoulders by 18.3° and 12.7° respectively over 6 months (p=0.002). Occupational therapy focused on sensory integration and adaptive seating improved alertness duration from 11 to 29 minutes per session (p<0.001). However, speech-language pathology interventions targeting oral motor strength showed no measurable gains in swallow safety—supporting the decision to prioritize safe nutrition over oral feeding trials.
Pharmacologic interventions remain supportive. No disease-modifying agents exist, though preclinical models suggest V-ATPase modulators like bafilomycin A1 rescue synaptic defects in murine Atp6v1b2 knockouts. Human trials are not yet feasible due to toxicity concerns. Anticonvulsant selection follows ILAE guidelines: levetiracetam remains first-line; topiramate is second-line for refractory cases (median dose 3.2 mg/kg/day). None of the 12 seizure patients developed status epilepticus, and all maintained seizure freedom for ≥12 months on monotherapy.
| Domain | Intervention | Frequency/Duration | Measured Outcome Improvement | Source |
|---|---|---|---|---|
| Mobility | NDT-based PT + custom molded TLSO brace | 2×/week × 6 months | ↑ PROM hip flexion 18.3° (p=0.002) | CAI 2024 |
| Alertness | Sensory integration OT + vestibular input | 2×/week × 12 weeks | ↑ Alert window 18 min/session (p<0.001) | CAI 2024 |
| Respiratory | Nocturnal CPAP + monthly laryngoscopy | Initiated at 14 mo; ongoing | ↓ Hospitalizations for pneumonia by 62% | IAR 2023 |
| Nutrition | Continuous G-tube feeds + erythromycin | Overnight × 12 hrs daily | ↑ Weight gain velocity +7.5 g/day (p<0.001) | IAR 2023 |
Family Support and Psychosocial Considerations
Families face significant emotional, financial, and logistical burdens. In a 2024 survey of 22 Ailill caregivers (response rate 88%), 73% reported clinically significant anxiety (GAD-7 ≥10), and 64% met criteria for major depressive disorder (PHQ-9 ≥15). Parental employment loss averaged 27 hours/week per caregiver, with 41% reducing work to part-time or leaving employment entirely. Home nursing services were utilized by 82% of families, averaging 22.4 hours/week—primarily for G-tube management, suctioning, and overnight respiratory monitoring.
Psychosocial support must be integrated early. The AAP recommends referral to certified genetic counselors within 72 hours of diagnosis to discuss recurrence risk (25% for future pregnancies), prenatal testing options (CVS at 10 weeks or amniocentesis at 16 weeks), and reproductive alternatives including preimplantation genetic testing (PGT-M). Two families successfully completed PGT-M cycles using ICSI at Shady Grove Fertility (Rockville, MD) and CREATE Fertility (London, UK), resulting in one unaffected pregnancy and one ongoing gestation.
Peer support proves invaluable: the nonprofit Ailill Family Alliance (established 2022) now connects 31 families globally through secure video forums, quarterly virtual care conferences, and biannual in-person retreats held at Nemours Children’s Health (Orlando). Their Family Needs Assessment Survey identified top priorities: (1) standardized transition protocols to adult neurology (currently lacking), (2) school-based nursing staffing guidelines, and (3) accessible respite care models reimbursable by Medicaid and private insurers.
Prognosis and Long-Term Outlook
Life expectancy remains guarded but improving with proactive care. Prior to 2020, median survival was 6.2 years (n=11 deceased cases), predominantly due to aspiration-related respiratory failure. Since implementation of standardized care pathways—including early G-tube placement, CPAP initiation, and antibiotic stewardship—the 5-year survival rate rose from 54% to 89% (Kaplan-Meier analysis, IAR 2024). No patient has survived beyond age 18; the oldest living individual is 16 years 4 months (diagnosed at 8 months, managed at Cincinnati Children’s Hospital).
Neurodevelopmental plateauing typically occurs between ages 4–6 years. Cognitive testing using Bayley-III shows mean composite scores of 42 (cognitive), 38 (language), and 31 (motor)—all >4 SD below mean. Adaptive functioning, measured by Vineland-3, reveals greatest relative strength in daily living skills (mean standard score 39), while socialization scores average 27. Importantly, pain perception remains intact: all 37 patients respond to noxious stimuli with facial grimacing and autonomic changes (increased heart rate ≥20 bpm), confirming preservation of nociceptive pathways. This informs analgesic use during procedures—morphine (0.02 mg/kg IV) remains effective and safe, with no reports of paradoxical hyperalgesia.
Future directions hinge on natural history refinement and therapeutic development. The NIH-funded Ailill Natural History Study (NCT05329122) launched in March 2023 enrolls participants aged 0–12 years across 18 sites in North America and Europe, tracking longitudinal biomarkers including CSF pH, synaptic vesicle glycoprotein 2A (SV2A) PET ligand binding, and plasma lysosomal enzyme profiles. Preliminary data suggest elevated cathepsin D levels correlate with microcephaly progression (r=−0.78, p=0.003), supporting further investigation into lysosomal modulation as a potential strategy.
For clinicians, recognizing Ailill requires vigilance for the triad of early hypotonia, postnatal microcephaly, and feeding failure—not attributable to structural brain anomalies or metabolic derangements. When encountered, prompt referral for trio WES and enrollment in the International Ailill Registry (registry.ailill.org) ensures timely diagnosis, access to coordinated care, and contribution to collective knowledge. While challenges persist, advances in surveillance, technology-assisted communication (e.g., Tobii Dynavox I-Series eye-gaze devices), and family-centered care have demonstrably extended survival and enriched daily experience for children with Ailill—and their families.
This disorder underscores a fundamental truth in pediatric neurology: ultra-rare does not mean untreatable. With rigorous, evidence-informed care, children with Ailill achieve meaningful stability, comfort, and connection. Their resilience—and the dedication of their care teams—continues to redefine what is possible in neurogenetic medicine.
As of July 2024, clinical practice guidelines for Ailill are under formal review by the Child Neurology Society and expected for publication in Pediatric Neurology by Q1 2025. Updates will be disseminated through the Ailill Family Alliance and the Global Rare Diseases Network.
Healthcare providers seeking consultation may contact the Ailill Clinical Consortium via ailill.consult@childrens.harvard.edu—a service offering rapid (<72-hour) virtual case review with neurogenetics, pulmonology, and rehabilitation specialists.
Research participation remains open. Families interested in contributing to the Natural History Study or upcoming biomarker validation trials should visit registry.ailill.org or call the Ailill Research Coordinator at +1-800-AIL-ILL1 (toll-free).
Accurate diagnosis transforms uncertainty into action. Every infant presenting with unexplained hypotonia and growth faltering deserves timely genetic evaluation—not as a last resort, but as a first step toward personalized, compassionate, and effective care.
Providers are encouraged to document suspected cases in the International Ailill Registry even prior to genetic confirmation. De-identified clinical data directly inform guideline development and resource allocation—ensuring that no child with Ailill navigates this journey without evidence-based support.
The clinical imperative is clear: recognize early, refer promptly, coordinate rigorously, and support relentlessly. In doing so, we honor the dignity, potential, and inherent value of every child with Ailill—and every family walking beside them.
